QC
BNTC icon

Quadrature Capital’s Benitec Biopharma BNTC Stock Holding History

Quadrature Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193K Sell
18,085
-13,396
-43% -$155K ﹤0.01% 1130
2025
Q4 		$424K Buy
+31,481
New +$435K ﹤0.01% 741

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Quadrature Capital's BNTC Position: Q1 2026 in Review

Quadrature Capital reduced its Benitec Biopharma (BNTC) stake by 43% in Q1 2026, selling an estimated $155K and leaving 18,085 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #1130.

Quadrature Capital first reported a position in BNTC in Q4 2025 and has held it in 2 quarters since. The position peaked at $424K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Quadrature Capital held 18,085 shares of Benitec Biopharma worth $193K as of Q1 2026.
  • Quadrature Capital sold 13,396 Benitec Biopharma shares in Q1 2026, an estimated $155K.
  • Benitec Biopharma made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1130 holding.
  • Quadrature Capital first reported a position in Benitec Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Benitec Biopharma position peaked at $424K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.